Individuals suffering from food allergies now have access to a medication that can potentially avert serious consequences. This medication, which has been available for twenty years, has received approval from the FDA. Xolair (omalizumab) by Roche and Novartis is the first food allergy treatment sanctioned to diminish allergic responses stemming from unintentional consumption of specific foods. It is authorized for individuals aged one year and above who have particular allergies.
The food allergy treatment is intended for individuals with IgE-mediated food allergies, a category encompassing 160 different foods, with the most prevalent being peanuts, milk, eggs, wh...
